within Pharmacolibrary.Drugs.N_NervousSystem.N03A_Antiepileptics.N03AX21_Retigabine;

model Retigabine
  extends Pharmacolibrary.Drugs.ATC.N.N03AX21;

  annotation (Documentation(
info       = "<html><body><table><tr><td>Drug:</td><td>N03AX21</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>1</td></tr></table><p>Retigabine (also known as ezogabine) is an anticonvulsant medication used as adjunctive therapy in the treatment of partial-onset seizures in epilepsy. It acts primarily as a potassium channel opener (KCNQ potassium channel agonist). Retigabine was approved in the EU and US but has been discontinued due to safety concerns including retinal abnormalities and skin discoloration.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetics reported for healthy adult volunteers after single oral dose.</p><h4>References</h4><ol><li><p>Tompson, DJ, &amp; Crean, CS (2013). Clinical pharmacokinetics of retigabine/ezogabine. <i>Current clinical pharmacology</i> 8(4) 319–331. DOI:<a href=\"https://doi.org/10.2174/15748847113089990053\">10.2174/15748847113089990053</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/23342983/\">https://pubmed.ncbi.nlm.nih.gov/23342983</a></p></li><li><p>Jacob, S, &amp; Nair, AB (2016). An Updated Overview on Therapeutic Drug Monitoring of Recent Antiepileptic Drugs. <i>Drugs in R&amp;D</i> 16(4) 303–316. DOI:<a href=\"https://doi.org/10.1007/s40268-016-0148-6\">10.1007/s40268-016-0148-6</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/27766590/\">https://pubmed.ncbi.nlm.nih.gov/27766590</a></p></li><li><p>Pergolizzi, JV, et al., &amp; Varrassi, G (2024). An update on pharmacotherapy for trigeminal neuralgia. <i>Expert review of neurotherapeutics</i> 24(8) 773–786. DOI:<a href=\"https://doi.org/10.1080/14737175.2024.2365946\">10.1080/14737175.2024.2365946</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/38870050/\">https://pubmed.ncbi.nlm.nih.gov/38870050</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>",
    experiment (StartTime = 0, StopTime = 86400, Tolerance = 1e-9, Interval = 1)
  ));
end Retigabine;
